Coby mentioned 2023 and qualification in one sentence.
So while there may well be good news ahead in lab qualification steps and other developments, the big $ revenue initiation may not begin this year.
The appointment of a Chief Scientist points the way to a broader front of R&D, and perhaps some key short term opportunities which require some more focus.
The market will be looking for those pre-revenue developments to initiate or validate further rises.
IMO. DYOR.
Weebit - 2022 and beyond, page-460
-
- There are more pages in this discussion • 2,459 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add WBT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.92 |
Change
0.000(0.00%) |
Mkt cap ! $361.7M | |||
| Open | High | Low | Value | Volume |
| $1.94 | $1.95 | $1.91 | $654.4K | 340.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 7769 | $1.92 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.92 | 11026 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| WBT (ASX) Chart |